

The increase in paraoxonase-1 is associated with a decrease in left ventricular volume in kidney transplant recipients.

Philip W. Connelly^{1,2}, Andrew T. Yan³, Michelle M. Nash⁴, Rachel Wald⁵, Charmaine Lok⁵, Lakshman Gunaratnam⁶, Anish Kirpalani⁷, G.V. Ramesh Prasad⁸.

Author affiliations:

¹Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital and University of Toronto; Keenan Research Centre for Biomedical Science of St. Michael's Hospital,

²Department of Laboratory Medicine and Pathobiology, University of Toronto;

³Division of Cardiology, St. Michael's Hospital, University of Toronto, Ontario, Canada

⁴Renal Transplant Program, St. Michael's Hospital, Ontario, Canada

⁵Division of Nephrology, Toronto General Hospital, University of Toronto, Ontario, Canada

⁶Division of Nephrology, London Health Sciences Centre, Western University, Ontario, Canada

⁷Department of Medical Imaging, St. Michael's Hospital University of Toronto, Ontario, Canada

⁸Department of Nephrology, St. Michael's Hospital, University of Toronto, Ontario, Canada

Corresponding author: Philip W. Connelly, Keenan Research Centre for Biomedical Science of St.

Michael's Hospital, Room 413, 209 Victoria Street, Toronto, ON, Canada, M5B 1T8, email:

Phil.connelly@unityhealth.to

Abstract

Background: Patients on dialysis have impaired cardiac function, in part due to increased fluid volume and ventricular stress. Restored kidney function through transplantation reduces left ventricular volume in both systole and diastole. Paraoxonase 1 (PON1) is reduced in patients on dialysis, which may be related to their impaired cardiac function. We tested the hypothesis that change in PON1 is associated with changes in left ventricular (LV) end-volume and LV mass after kidney transplantation.

Methods: Patients were studied before and 12 months after kidney transplantation. The control group was patients on dialysis not expected to receive a transplant in the next 12 months. Cardiac magnetic resonance imaging was used to measure LV end-diastolic and end-systolic volume and LV mass. PON1 was measured by arylesterase activity and by mass.

Results: PON1 mass and activity were not different between the groups at baseline. Both PON1 mass and activity were increased post-kidney transplantation ($p < 0.0001$ for change). The change in PON1 mass ($p = 0.0062$) and PON1 arylesterase activity ($p = 0.0254$) were inversely correlated with the change in NT-proBNP for patients receiving a kidney transplant. However, only the change in the PON1 mass, but not the change in PON1 arylesterase, was inversely correlated with the change in left ventricular volume ($\text{ml}/\text{m}^{2.7}$) ($p = 0.0146$ and 0.0114 for diastolic and systolic, respectively) and with the change in hemoglobin ($p = 0.0042$).

Conclusions: PON1 mass and activity increase after kidney transplantation. The increase in PON1 mass is consistent with a novel relationship to the increase in hemoglobin and the decrease in LV end-systolic and end-diastolic volume.

Keywords: Paraoxonase-1, Transplantation, Dialysis, Left Ventricular Hypertrophy.

Introduction

Paraoxonase 1 (PON1) is a 43kDa protein synthesized primarily by the liver and released by hepatocytes to high density lipoproteins (HDL), to which it binds by an uncleaved N-terminal leader sequence. PON1 has both metal binding and hydrolase properties, functioning as an arylesterase and a hydrolase for paraoxon and chlorpyrifos oxon, respectively. Sequence homology revealed a native function for PON1 as a lactonase [1, 2].

Kidney function is an important determinant of lipoprotein concentrations [3]. However, the amount of PON1 activity seen in states of reduced kidney function, including end-stage kidney disease (ESKD) requiring hemodialysis (HD) or peritoneal dialysis (PD), and partially restored kidney function, such as after kidney transplantation, remains to be fully established.

The first report that PON1 activity was reduced in patients on hemodialysis was by Schiavon et al. [4]. Hasselwander et al. [5], who also found both paraoxonase and arylesterase were lower in patients on dialysis. We observed lower PON1 in patients on standard hemodialysis and home nocturnal hemodialysis that was inversely correlated with C-reactive protein (CRP), a marker of inflammation [6]. In a cross-sectional study comparing a control group with patients on HD and patients with a kidney transplant, Sztanek et al. [7] found PON1 activity (measured as paraoxonase or lactonase) to be lowest for HD patients, followed by those with kidney transplant and highest in control subjects. Samouilidou et al. [8] measured PON1 mass and found it to be markedly reduced in HD patients compared to controls and patients with CKD.

Bhattacharyya et al. [9] reported that PON1 Q192R genotype, paraoxonase, and arylesterase activities were related to cardiovascular outcomes in a cohort of subjects undergoing elective diagnostic cardiac catheterization. The lowest quartile of arylesterase activity had a 4.5-fold hazard ratio for nonfatal myocardial infarction or cerebrovascular accident. Hammadah et al. [10] reported event-free survival

over five years for subjects with chronic heart failure from the Atlanta Cardiomyopathy Consortium. BNP was highest, and HDL cholesterol was lowest for the lowest tertile of arylesterase activity. The lowest tertile of baseline arylesterase activity was associated with a 2.6 hazard ratio for heart failure events (death, cardiac transplant, ventricular assist device).

Patients with chronic kidney disease (CKD) are at increased risk for cardiovascular disease, particularly nonatherosclerotic disease characterized by left ventricular hypertrophy [11]. Cardiac magnetic resonance imaging (CMR) is particularly useful as a noninvasive approach to measure left ventricular volume and mass due to its accuracy and precision [12]. We have recently reported the left ventricular changes in patients on dialysis receiving a kidney transplant. While both left ventricular volume and adiponectin levels decreased with a kidney transplant, the change in adiponectin level and the change in HDL cholesterol were not associated with the change in left ventricular volume [13]. CMR is, therefore, a useful tool to correlate biomarker changes after transplantation with measurable changes in cardiac function.

In summary, the majority of studies of patients on dialysis have measured PON1 enzymatic activity. There is inconsistency in the reports, but the consensus is that activity is lowest for patients on dialysis, higher for patients that have received a kidney transplant, and highest for normal control subjects. This gradient in PON1 enzymatic activity is consistent with the gradient of kidney function. However, these studies were all cross-sectional in design. No study to date has prospectively determined the change in PON1 mass or activity with kidney transplantation, a procedure that partially restores kidney function so that patients with ESKD no longer require dialysis. Further, there has been no study that compared the change in PON1 and the change in left ventricular indices.

Materials and Methods

The recruitment of participants for this study has been described [14, 13]. The study sample size target of 42 subjects per group was designed to detect a 5 µg/ml change in adiponectin, with expected attrition of 20%. The methods for CMR measurement of left ventricular volume and left ventricular mass have been described in detail [14]. Briefly, CMR was performed with a 1.5-tesla whole-body magnetic resonance scanner (Intera: Philips Medical Systems, Best, The Netherlands) using a phased-array cardiac coil and retrospective vectorographic gating. All CMR studies were analyzed by readers blinded to the information about the patient and the time point of data acquisition. CMR data were analyzed by an experienced reader using cvi42 software (Circle Cardiovascular, Calgary, Canada). Left ventricular volumes and mass were allometrically adjusted by dividing by height in meters^{2.7} [15]. Adiponectin was measured using the Meso Scale Discovery human adiponectin assay (#K151BXC-2, Meso Scale Diagnostics, Rockville, Maryland) and calibrated to the Millipore enzyme-linked immunoassay (#EZHADP-61-K, Millipore, St. Charles, MO, USA). N-terminal proB-type natriuretic peptide was measured on the Roche Cobas 6000 601e module (Mississauga, ON, Canada). Measurement of PON1 was an a priori secondary variable. PON1 activity as hydrolysis of phenyl acetate and as enzyme mass were measured as described [16, 17]. PON1 phenotype was determined by the two substrate method of Richter et al. [18].

Statistical analysis was done using SAS version 9.4 (Cary, NC, USA). Graphs were plotted using GraphPad Prism vs 8.0). Between-group comparisons were made using unpaired t-test.

The study was approved by the Research Ethics Board at St. Michael's Hospital (REB 10-239) and by the ethics boards at the collaborating sites. All subjects provided written informed consent. The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

Results

The characteristics of the study population are shown in Table 1. Hemoglobin and albumin concentrations at baseline were significantly different between the participants on peritoneal dialysis versus hemodialysis. Therefore, a sensitivity analysis was performed, and the univariate analyses are presented separately by baseline dialysis type.

Within dialysis type, baseline values for the dialysis versus transplant subjects were not significantly different, with the exception of a lower left ventricular volume at diastole ($\text{ml/m}^{2.7}$) for the peritoneal dialysis subjects. Allometrically adjusted left ventricular mass ($\text{g/m}^{2.7}$) was not different between the two groups.

Kidney transplantation resulted in similar, statistically significant increases in hemoglobin concentration for both dialysis groups. Of note, kidney transplantation did not significantly affect albumin in the hemodialysis group, whereas there was a significant increase in albumin in the kidney transplant group that had been on peritoneal dialysis. The C-reactive protein concentration was not significantly different between the groups and was not significantly affected by kidney transplantation.

Univariate analyses of PON1 mass and activity comparing the dialysis and transplant groups are shown in Table 2. Baseline values were not significantly different between the two groups. Month 12 values for PON1 activity ($p=0.0125$) and PON1 mass ($p=0.0119$) were significantly higher in the transplant group, especially when analyzed as the change in activity or mass ($p<0.0001$). Notably, the standard deviation for the dialysis group and the transplant group was similar.

The most striking impact of dialysis modality was on the change in albumin, which was highly significant for subjects on peritoneal dialysis ($p=0.0005$), but not significant for subjects on hemodialysis ($p=0.34$) (Table 3). The change in systolic and diastolic left ventricular volume was greater for subjects on peritoneal dialysis and reached statistical significance in spite of the smaller sample size. The decrease in both measures for subjects on hemodialysis was consistent with a beneficial, albeit smaller, effect of

kidney transplantation for this group. The change in PON1 activity and mass was significant for both dialysis modalities. The change in hemoglobin was also significant for both groups, although it was greater for the peritoneal dialysis subjects. The change in HDL cholesterol was also found to be significant for subjects in both dialysis groups. Thus, among parameters that are products of the liver, albumin was distinguished from PON1 and HDL cholesterol as having a strong effect due to dialysis type. Correlation analysis is presented separately for the transplant group (Table 4) and the dialysis group (Table 5).

For the kidney transplant group, the change in PON1 mass and arylesterase were highly significantly correlated ($p < 0.0001$). Of importance for this study, change in hemoglobin was positively correlated with change on PON1 mass ($p = 0.0042$), but not PON1 activity ($p = 0.2751$). Further, the change in PON1 mass was inversely correlated with the change in left ventricular diastolic volume ($p = 0.0146$), systolic volume ($p = 0.0114$), and LnNT-proBNP ($p = 0.0062$). Although the change in PON1 mass was correlated with the change in HDL cholesterol concentration ($p = 0.0562$), the change in HDL cholesterol was not significantly correlated with left ventricular volume or mass. The change in HDL cholesterol was significantly correlated with the change in PON1 arylesterase ($p = 0.0003$) and adiponectin ($p = 0.0062$).

The median percent change in PON1 mass was -3.9% versus 20.3% for the dialysis and transplant groups, respectively. The change in PON1 mass was not correlated with the average PON1 mass ($p = 0.56$), indicating that baseline PON1 concentrations were not a determinant of the response to kidney transplantation. Thus, the incremental increase in PON1 mass was similar across the PON1 concentration range.

For the dialysis group, the changes primarily reflect biologic variation, as only the change in LnNT-proBNP was significantly different from the null ($p = 0.0487$). The correlation between PON1 mass and arylesterase activity was significant ($p < 0.0001$). Consistent with these two measures having different

determinants, PON1 arylesterase variation correlated inversely with the change in left ventricular diastolic volume ($p=0.0195$) and LnNT-proBNP ($p=0.0453$), whereas there was no correlation for the change in PON1 mass ($p=0.9981, 0.3421$, respectively).

PON1 Q192R phenotype frequency was not different between dialysis and transplant subjects (Supplemental Table 1). Further, the Q192R phenotype was not a significant factor for the change in PON1 mass (data not shown).

Discussion

We have shown for the first time that the increase in PON1 mass post-kidney transplant negatively correlates with the change in left ventricular volume and positively correlates with the change in hemoglobin. Further, we have documented that the change in PON1 mass post-kidney transplant is independent of C-reactive protein, a marker of inflammation. The change in PON1 mass is also independent of the baseline concentration of PON1. The separation of the change in PON1 from changes in CRP, HDL cholesterol, and albumin would be consistent with specific effects that link PON1, hemoglobin, and left ventricular volume in CKD states. PON1 arylesterase did not uniquely share a common factor with the change in hemoglobin or left ventricular end-volume.

Several candidates are suggested by the current literature to explain these relationships. PON1 is involved, as a lactonase, in the metabolic conversion of 5,6-epoxyeicosatrienoic acid (5,6-EET), an epoxy fatty acid that is not a substrate for soluble epoxide hydrolase, and which spontaneously forms a lactone [19-21]. It has been reported that 5,6-EET regulates blood pressure [21]. The epoxyeicosatrienoic acids are also among the molecules that regulate response to mechanotransduction as regulators of TRPV4 [22, 23]. Independently, the production of B-type natriuretic peptide, as reflected by the inverse relationship of PON1 with NT-proBNP, could indicate a link between PON1 and mechano-sensing pathways. Thus, one could speculate that PON1 mass reflects a role in response to left ventricular volume. The cause and

effect relationship among changes in left ventricular volume hemoglobin and PON1 mass cannot, however, be elucidated from the current study design.

PON1 has a well-recognized labile metal-binding site, in addition to its enzymatic activity. This labile site requires calcium for enzyme activity, but it can also bind metals. Thus, one potential function of PON1 is in the regulation of iron, zinc, and other divalent cations [24-26]. Rahimi-Ardabili et al. [27] reported that 61 days of 100 mg zinc sulfate increased HDL cholesterol, apoAI, and paraoxonase activity in patients on hemodialysis. Thus, while there is a clear response to zinc, it was not specific to paraoxonase and may be a general effect on HDL production or clearance. This putative function would be dependent upon the mass of PON1 and would have the potential not only to be independent of the lactonase activity but also to be inverse to such activity.

The positive correlation of the change in PON1 mass with the change in hemoglobin could indicate that factors involved in iron metabolism regulate PON1 gene expression in concert with regulating hemoglobin concentration. This would be consistent with an increase in PON1 in response to erythropoietin therapy that has been reported in a single study [28, 29]. However, currently, there is no known link between the regulation of human PON1 gene expression and iron metabolism.

Kidney transplant recipients benefit markedly from their improved kidney function compared to remaining on dialysis, experiencing improved long-term cardiovascular morbidity and mortality (29). While improvement in left ventricular volume and hemoglobin are well-known effects of kidney transplantation, the nature of their relationship to these improved cardiovascular outcomes remains unestablished. In this study, we have shown that PON1 mass and activity may be key mediators in the pathway linking restored kidney function and improved cardiovascular parameters and outcomes. In the future, interventions selectively directed toward increasing PON1 mass may help further understand the mechanisms that connect the kidney and heart in patients with pathological cardiorenal syndromes.

Conflict of Interest Statement

The authors declare no potential conflicts of interest with respect to the research, authorship, or publication of this article. The results in this paper have not been published previously in whole or part, except in abstract format.

Author's Contributions

PWC, ATY, MMN participated in the research design, funding, performance of the research, writing, and data analysis. RW, CL, LG participated in the research design, performance of the research and manuscript revision. GRK participated in performance of the research and data analysis. GVRP coordinated the research design, funding, performance of the research, writing and data analysis.

Funding

This study was funded by the Heart and Stroke Foundation of Canada, Grant Number HSFNA7077, and by the Canadian Institutes of Health Research Grant Number MOP-136954. Dr. Yan is supported by a Clinician-Scientist Award from the University of Toronto. Dr. Lakshman Gunaratnam is supported by Schulich new investigator Award, Schulich School of Medicine and Dentistry, Western University, and the KRESCENT/CIHR New Investigator Award.

Abbreviations

CKD, chronic kidney disease

CMR, cardiac magnetic resonance imaging

ESKD , end-stage kidney disease

HD, hemodialysis

HDL, high density lipoprotein

LV, left ventricular

NT-proBNP, NT pro-B type natriuretic peptide

PON1, paraoxonase 1

PD, peritoneal dialysis

References

1. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. *Curr Opin Lipidol*. 1996 Apr;7(2):69-76.
2. Kobayashi M, Shinohara M, Sakoh C, Kataoka M, Shimizu S. Lactone-ring-cleaving enzyme: genetic analysis, novel RNA editing, and evolutionary implications. *Proc Natl Acad Sci U S A*. 1998 Oct 27;95(22):12787-92.
3. Kronenberg F. HDL in CKD-The Devil Is in the Detail. *J Am Soc Nephrol*. 2018 May;29(5):1356-71.
4. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase activity is decreased in uremic patients. *Clin Chim Acta*. 1996 Mar 29;247(1-2):71-80.
5. Hasselwander O, McMaster D, Fogarty DG, Maxwell AP, Nicholls DP, Young IS. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. *Clin Chem*. 1998 Jan;44(1):179-81.
6. Kannampuzha J, Darling PB, Maguire GF, Donnelly S, McFarlane P, Chan CT, et al. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis. *Clin Nephrol*. 2010 Feb;73(2):131-8.
7. Sztanek F, Seres I, Harangi M, Locsey L, Padra J, Paragh GJ, et al. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease. *Nephrol Dial Transplant*. 2012 Jul;27(7):2866-72.
8. Samouilidou E, Kostopoulos V, Liaouri A, Kioussi E, Vassiliou K, Bountou E, et al. Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease. *Ren Fail*. 2016 Nov;38(10):1601-06.

9. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. *JAMA*. 2008 Mar 19;299(11):1265-76.
10. Hammadah M, Kalogeropoulos AP, Georgiopoulou VV, Weber M, Wu Y, Hazen SL, et al. High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure. *Eur J Heart Fail*. 2017 Jun;19(6):748-55.
11. Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. *JACC Cardiovasc Imaging*. 2014 Jul;7(7):703-14.
12. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, Turkbey EB, Williams R, et al. Normal values for cardiovascular magnetic resonance in adults and children. *J Cardiovasc Magn Reson*. 2015 Apr 18;17:29.
13. Prasad GVR, Yan AT, Nash MM, Kim SJ, Wald R, Wald R, et al. Determinants of Left Ventricular Characteristics Assessed by Cardiac Magnetic Resonance Imaging and Cardiovascular Biomarkers Related to Kidney Transplantation. *Can J Kidney Health Dis*. 2018;5:2054358118809974.
14. Gong IY, Al-Amro B, Prasad GVR, Connelly PW, Wald RM, Wald R, et al. Cardiovascular magnetic resonance left ventricular strain in end-stage renal disease patients after kidney transplantation. *J Cardiovasc Magn Reson*. 2018 Dec 17;20(1):83.
15. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. *J Am Coll Cardiol*. 1992 Nov 1;20(5):1251-60.
16. Connelly PW, Maguire GF, Draganov DI. Separation and quantitative recovery of mouse serum arylesterase and carboxylesterase activity. *J Lipid Res*. 2004 Mar;45(3):561-6.

17. Connelly PW, Maguire GF, Nash MM, Rapi L, Yan AT, Prasad GV. Paraoxonase 1 Phenotype and Mass in South Asian versus Caucasian Renal Transplant Recipients. *J Lipids*. 2012;2012:608580.
18. Richter RJ, Jarvik GP, Furlong CE. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. *Circ Cardiovasc Genet*. 2008 Dec;1(2):147-52.
19. Eryanni-Levin S, Khatib S, Levy-Rosenzvig R, Tamir S, Szuchman-Sapir A. 5,6-delta-DHTL, a stable metabolite of arachidonic acid, is a potential substrate for paraoxonase 1. *Biochim Biophys Acta*. 2015 Sep;1851(9):1118-22.
20. Levi-Rosenzvig R, Beyer AM, Hockenberry J, Ben-Shushan RS, Chuyun D, Atiya S, et al. 5,6-delta-DHTL, a stable metabolite of arachidonic acid, is a potential EDHF that mediates microvascular dilation. *Free Radic Biol Med*. 2017 Feb;103:87-94.
21. Gilad D, Atiya S, Mozes-Autmazgin Z, Ben-Shushan RS, Ben-David R, Amram E, et al. Paraoxonase 1 in endothelial cells impairs vasodilation induced by arachidonic acid lactone metabolite. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2019 Mar;1864(3):386-93.
22. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. *Nature*. 2003 Jul 24;424(6947):434-8.
23. Vriens J, Watanabe H, Janssens A, Droogmans G, Voets T, Nilius B. Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4. *Proc Natl Acad Sci U S A*. 2004 Jan 6;101(1):396-401.
24. Ekinici D, Beydemir S. Purification of PON1 from human serum and assessment of enzyme kinetics against metal toxicity. *Biol Trace Elem Res*. 2010 Jun;135(1-3):112-20.

25. Luciano-Mateo F, Cabre N, Nadal M, Garcia-Heredia A, Baiges-Gaya G, Hernandez-Aguilera A, et al. Serum concentrations of trace elements and their relationships with paraoxonase-1 in morbidly obese women. *J Trace Elem Med Biol.* 2018 Jul;48:8-15.
26. Rovira J, Hernandez-Aguilera A, Luciano-Mateo F, Cabre N, Baiges-Gaya G, Nadal M, et al. Trace Elements and Paraoxonase-1 Activity in Lower Extremity Artery Disease. *Biol Trace Elem Res.* 2018 Nov;186(1):74-84.
27. Rahimi-Ardabili B, Argani H, Ghorbanihaghjo A, Rashtchizadeh N, Naghavi-Behzad M, Ghorashi S, et al. Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients. *Ren Fail.* 2012;34(9):1123-8.
28. Marsillach J, Martinez-Vea A, Marcas L, Mackness B, Mackness M, Ferre N, et al. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. *Clin Exp Pharmacol Physiol.* 2007 Apr;34(4):347-9.
29. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. *Lancet.* 2011 Oct 15;378(9800):1419-27.

Table 1. Characteristics of study subjects by treatment group and baseline dialysis modality.

	Hemodialysis at baseline			Peritoneal dialysis at baseline		
	Dialysis	Transplant		Dialysis	Transplant	
Women/Men	8/23	10/17		4/8	2/10	
Age, yrs	54.1 ± 9.6	46.3 ± 12.1	0.008	59.2 ± 13.8	47.1 ± 13.7	0.04
Baseline						
Serum Creatinine $\mu\text{mol/L}$	674 ± 229	694 ± 230	0.75	789 ± 199	926 ± 332	0.23
BMI, kg/m^2	27.2 ± 5.2	25.5 ± 4.9	0.2	25.7 ± 4.1	27.1 ± 3.6	0.39
Hemoglobin, g/L	118.7 ± 15.3 [^]	121.5 ± 13.4 [*]	0.46	109.3 ± 11.7	106.7 ± 17.0	0.67
Total Chol, mM	4.0 ± 1.3	4.16 ± 1.22	0.63	4.15 ± 1.04	4.21 ± 1.11	0.89
Triglycerides, mM	1.46 ± 0.85	1.93 ± 1.39	0.12	1.53 ± 0.53	2.03 ± 0.84	0.10
LDL Chol, mM	2.17 ± 1.12	2.17 ± 0.97	0.98	2.35 ± 1.0	2.38 ± 0.95	0.93
HDL Chol, mM	1.19 ± 0.33	1.13 ± 0.32	0.51	1.11 ± 0.36	0.90 ± 0.19	0.10
Albumin, g/L	41.6 ± 4.2 [#]	41.7 ± 3.8 [§]	0.91	35.8 ± 2.4	36.9 ± 3.5	0.40
CRP, mg/L	6.5 ± 10.2	3.8 ± 5.0	0.21	6.5 ± 7.3	6.0 ± 6.0	0.88
LV systolic volume, $\text{ml/m}^{2.7}$	15.9 ± 5.5	17.5 ± 6.5	0.33	15.2 ± 5.0	19.3 ± 5.8	0.08
LV diastolic volume, $\text{ml/m}^{2.7}$	39.2 ± 10.2	40.6 ± 10.7	0.63	37.0 ± 7.8	45.0 ± 9.4	0.036
LV mass index, $\text{g/m}^{2.7}$	30.8 ± 9.9	29.2 ± 8.6	0.50	28.7 ± 4.5	31.4 ± 8.2	0.32
Ln NT-proBNP, pg/ml	7.49 ± 1.55	7.23 ± 1.27	0.50	6.81 ± 1.38	7.30 ± 1.37	0.41
Adiponectin, $\mu\text{g/ml}$	23.0 ± 13.5	20.6 ± 11.0	0.47	20.4 ± 10.7	27.5 ± 10.8	0.13
PON1 $\mu\text{g/ml}$	98.2 ± 24.2	92.0 ± 22.9	0.32	80.8 ± 19	79.5 ± 26	0.89
PON1 arylesterase, U/ml	88.1 ± 19.2	82.3 ± 19.5	0.25	82.2 ± 19.5	78.4 ± 19.7	0.65
PON1 specific activity, U/ μg	0.91 ± 0.16	0.91 ± 0.18	0.99	1.02 ± 0.11	1.02 ± 0.18	0.92

Month 12						
Serum creatinine $\mu\text{mol/L}$	757 $\pm$ 234	129 $\pm$ 103	<0.0001	696 $\pm$ 177	118 $\pm$ 31	<0.0001
BMI, kg/m^2	27.6 $\pm$ 5.7	26.7 $\pm$ 4.7	0.49	25.0 $\pm$ 3.4	28.2 $\pm$ 5.4	0.11
Hemoglobin, g/L	116.6 $\pm$ 12.1	134.3 $\pm$ 20.3	0.0003	113.1 $\pm$ 13.3	137.6 $\pm$ 18.6	0.0012
Total Chol, mM	3.98 $\pm$ 1.32	4.39 $\pm$ 1.13	0.21	3.94 $\pm$ 1.07	4.33 $\pm$ 1.17	0.40
Triglycerides, mM	1.56 $\pm$ 0.96	1.85 $\pm$ 1.38	0.34	1.54 $\pm$ 0.58	1.90 $\pm$ 0.87	0.24
LDL Chol, mM	2.08 $\pm$ 0.93	2.33 $\pm$ 0.81	0.29	2.18 $\pm$ 0.90	2.14 $\pm$ 0.72	0.90
HDL Chol, mM	1.13 $\pm$ 0.37	1.24 $\pm$ 0.39	0.29	1.05 $\pm$ 0.29	1.19 $\pm$ 0.28	0.25
Albumin, g/L	42.8 $\pm$ 3.5	43.6 $\pm$ 2.9	0.36	36.5 $\pm$ 2.75	43.5 $\pm$ 3.0	<0.0001
CRP, mg/L	4.1 $\pm$ 3.9	3.0 $\pm$ 4.0	0.32	9.7 $\pm$ 13.3	4.8 $\pm$ 4.9	0.26
LV systolic volume, $\text{ml/m}^{2.7}$	15.5 $\pm$ 5.2	14.5 $\pm$ 4.4	0.47	15.4 $\pm$ 11.4	14.7 $\pm$ 12.8	0.72
LV diastolic volume, $\text{ml/m}^{2.7}$	39.6 $\pm$ 10.4	36.9 $\pm$ 8.1	0.29	37.3 $\pm$ 29.5	37.1 $\pm$ 34.6	0.96
LV mass index, $\text{g/m}^{2.7}$	30.2 $\pm$ 9.5	28.0 $\pm$ 6.0	0.29	28.5 $\pm$ 8.9	27.4 $\pm$ 4.5	0.70
Ln NT-proBNP, pg/ml	7.74 $\pm$ 1.53	4.81 $\pm$ 1.28	<0.0001	7.40 $\pm$ 1.77	4.95 $\pm$ 1.25	0.0007
Adiponectin $\mu\text{g/ml}$	21.7 $\pm$ 13.4	15.1 $\pm$ 7.1	0.021	23.3 $\pm$ 17.2	18.1 $\pm$ 11.3	0.39
PON1 $\mu\text{g/ml}$	96.2 $\pm$ 21.1	106.8 $\pm$ 22.4	0.07	83.0 $\pm$ 17.1	100.3 $\pm$ 23.8	0.06
PON1 arylesterase, U/ml	88.1 $\pm$ 19.9	99.2 $\pm$ 19.5	0.038	82.5 $\pm$ 17.0	95.4 $\pm$ 26.4	0.18
PON1 specific activity, U/ μg	0.93 $\pm$ 0.2	0.95 $\pm$ 0.16	0.80	1.00 $\pm$ 0.13	0.95 $\pm$ 0.19	0.46

Baseline hemoglobin: * $p=0.006$ for hemodialysis vs peritoneal dialysis for the transplant group; ^ $p=0.06$ for hemodialysis vs peritoneal dialysis for the dialysis group; Baseline albumin: # $p=0.0011$ for hemodialysis vs peritoneal dialysis for the transplant group; § $p<0.0001$ for hemodialysis vs peritoneal dialysis for the dialysis group.

Table 2. Paraoxonase 1 mass and activity by treatment group.

	Dialysis	Transplant	P
n	43	38	
Baseline			
PON1 arylesterase activity, U/ml	86.4 +/- 19.3	81.2 +/- 19.4	0.22
PON1 mass, µg/ml	93.4 +/- 24.0	88.6 +/- 24.1	0.35
PON1 specific activity, U/µg	0.94 +/- 0.16	0.94 +/- 0.18	0.99
Month 12			
PON1 arylesterase activity, U/ml	86.6 +/- 19.1	98.09 +/- 21.4	0.0125
PON1 mass, µg/ml	92.5 +/- 20.7	104.9 +/- 22.7	0.0119
PON1 specific activity, U/µg	0.95 +/- 0.18	0.95 +/- 0.16	0.89
Change PON1 arylesterase, U/ml	0.15 +/- 10.5	16.9 +/- 13.8	<0.0001
Change PON1 mass, µg/ml	-0.84 +/- 13.3	16.6 +/- 15.8	<0.0001

Table 3. Change in paraoxonase-1 mass and activity and relationship with hemoglobin and albumin by baseline dialysis modality

	Hemodialysis at baseline			Peritoneal dialysis at baseline		
	Dialysis	Transplant		Dialysis	Transplant	
n	N=28	N=26		12	11	
Change in albumin, g/L	1.04 ± 3.81	2.11 ± 4.41	0.34	0.67 ± 2.74	6.9 ± 4.4	0.0005
	N=30	N=27		N=12	N=11	
Change in LV systolic volume, ml/m ^{2.7}	-0.43 ± 4.09	-2.93 ± 5.91	0.067	0.28 ± 5.1	-4.42 ± 4.76	0.033
Change in LV diastolic volume, ml/m ^{2.7}	0.28 ± 9.3	-3.63 ± 7.98	0.096	0.33 ± 9.2	-7.91 ± 9.45	0.046
	N=31	N=27		N=12	N=11	
Change in PON1 activity, U/ml	0.07 ± 11.0	16.9 ± 13	<0.0001	0.35 ± 9.46	16.9 ± 16.2	0.0065
	N=31	N=27		N=12	N=11	
Change in PON1 mass, µg/ml	-2.01 ± 12.9	14.9 ± 16.9	<0.0001	2.2 ± 14.6	20.8 ± 12.32	0.0036
Change PON1 specific activity, U/µg	0.019 ± 0.12	0.03 ± 0.09	0.69	-0.018 ± 0.1	-0.061 ± 0.14	0.4
	N=31	N=27		N=12	N=12	
Change in Hemoglobin, g/L	-2.1 ± 16.8	12.8 ± 23.2	0.0066	3.8 ± 12.1	30.9 ± 29.7	0.0106
Change HDL cholesterol, mM	-0.05 ± 0.22	0.16 +/- 0.29	0.0081	-0.05 ± 0.18	0.29 ± 0.3	0.0026

Table 4. Pearson correlation of change in left ventricular measurements and hemoglobin with PON1, HDL cholesterol, and adiponectin for subjects receiving a kidney transplant.

Transplant group	LV diastolic volume	LV systolic volume	LVMI ^{2.7}	Hemoglobin g/L	LnNT-proBNP	PON1 µg/ml	PON1 units/ml	HDLC mM	Adiponectin µg/ml
LV_diastolic Volume, ml/m ^{2.7}	1.0	0.8460	0.7188	-0.4969	0.6074	-0.3931	-0.1294	-0.0116	0.3019
		<.0001	<.0001	0.0015	0.0001	0.0146	0.4387	0.9452	0.0654
	38	38	37	38	35	38	38	38	38
LV_systolic Volume, ml/m ^{2.7}		1.0	0.5729	-0.5379	0.6251	-0.4060	-0.3002	-0.0912	0.2039
			0.0002	0.0005	<.0001	0.0114	0.0671	0.5859	0.2195
		38	37	38	35	38	38	38	38
LVMI, g/m ^{2.7}			1.0	-0.4171	0.3962	-0.2425	-0.1157	-0.0485	0.2169
				0.0102	0.0204	0.1482	0.4962	0.7754	0.1972
			37	37	34	37	37	37	37
Hemoglobin g/L				1.0	-0.3850	0.4536	0.1816	0.0661	-0.2836
					0.0224	0.0042	0.2751	0.6892	0.0845
				39	35	38	38	39	38
LnNT-proBNP, pg/ml					1.0	-0.4536	-0.3774	-0.0572	0.3865
						0.0062	0.0254	0.7442	0.0218
					35	35	35	35	35
PON1, µg/ml						1.0	0.7318	0.3125	-0.1513
							<.0001	0.0562	0.3647

						38	38	38	38
PON1, units/ml							1.00000	0.5572 0.0003	0.2414 0.1443
							38	38	38
HDLC, mM								1.0 39	0.4363 0.0062
									38
Adiponectin, µg/ml									1.0
									38

Values shown in the table are the Pearson correlation coefficient, the p-value, and the number of subjects. Abbreviations: LV, left ventricular; LVMI, left ventricular mass index; LnNT-proBNP, natural log of NT-proB-type natriuretic peptide; PON1, paraoxonase 1; HDLC, high density lipoprotein cholesterol.

Table 5. Pearson correlation of change in left ventricular measurements and hemoglobin with PON1, HDL cholesterol, and adiponectin for subjects on dialysis.

Transplant group	LV diastolic volume	LV systolic volume	LVMl ^{2.7}	Hemoglobin g/L	LnNT-proBNP	PON1 µg/ml	PON1 units/ml	HDLC mM	Adiponectin µg/ml
LV_diastolic Volume, ml/m ^{2.7}	1.0	0.8316 <.0001	0.4975 0.0008	-0.3676 0.0166	0.5817 0.0001	-0.0004 0.9981	-0.3591 0.0195	0.1654 0.2951	0.2458 0.1166
	42	42	42	42	39	42	42	42	42
LV_systolic Volume, ml/m ^{2.7}		1.0	0.6079 <.0001	-0.3469 0.0244	0.6212 <.0001	-0.0329 0.8363	-0.2700 0.0837	0.0734 0.6443	0.3768 0.0139
		42	42	42	39	42	42	42	42
LVMl, g/m ^{2.7}			1.0	-0.3493 0.0234	0.7602 <.0001	-0.1270 0.4230	-0.2118 0.1782	-0.0151 0.9243	0.4610 0.0021
			42	42	39	42	42	42	42
Hemoglobin, g/L				1.0	-0.33710 0.0334	0.1830 0.2402	0.2703 0.0796	0.2573 0.0958	0.1063 0.4975
				43	40	43	43	43	43
LnNT-proBNP, pg/ml					1.0	-0.1542 0.3421	-0.3183 0.0453	-0.1224 0.4519	0.3963 0.0114
					40	40	40	40	40
PON1, µg/ml						1.0	0.6100 <.0001	0.3619 0.0171	0.1381 0.3771

						43	43	43	43
PON1, units/ml							1.0	0.40 0.0082	0.1757 0.2597
							43	43	43
HDLC, mM								1.0 43	0.3252 0.0333
									43
Adiponectin, µg/ml									1.0 43

Values shown in the table are the Pearson correlation coefficient, the p-value and the number of subjects. Abbreviations: LV, left ventricular; LVMI, left ventricular mass index; LnNT-proBNP, natural log of NT-proB-type natriuretic peptide; PON1, paraoxonase 1; HDLC, high density lipoprotein cholesterol.